Alnylam starts dosing RNAi therapy; Thermo Fisher Scientific broadens delivery tech with fragment library;

> Alnylam Pharmaceuticals has started dosing patients in a Phase I study of the RNAi therapy ALN-TTR01, which uses Tekmira's leading lipid nanoparticle delivery technology. Release

> Thermo Fisher Scientific has added the Maybridge Ro3 Diversity Fragment Library to its offerings, expanding its drug delivery technology offerings. Story

> Silence Therapeutics says that it has expanded its RNA silencing IP portfolio with the issuance of a new patent. Release

> Biocompatibles International has acquired patents protecting its bead products in a $4.5 million deal with Biocure. Release